Loading...
Loading...
REPL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.7M |
| Gross Profit | -0.7M |
| Operating Expense | 63.4M |
| Operating I/L | -63.8M |
| Other Income/Expense | 3.6M |
| Interest Income | 6.0M |
| Pretax | -60.2M |
| Income Tax Expense | -0.2M |
| Net Income/Loss | -60.0M |
Replimune Group, Inc. is a biotechnology company specializing in oncolytic immuno-gene therapies for cancer treatment. Leveraging its proprietary Immunotherapy platform, the company develops product candidates, including RP1, a selectively replicating version of herpes simplex virus 1, currently in Phase I/II clinical trials for solid tumors and Phase II trials for cutaneous squamous cell carcinoma. Additionally, it is working on RP2, a Phase I anti-CTLA-4 antibody-like protein, and RP3, a Phase I immune-activating protein expression therapy to stimulate T cells.
